1-8 of 8
Timothy M. Illidge
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

Simon J. Dovedi, Monique H. M. Melis, Robert W. Wilkinson, Amy L. Adlard, Ian J. Stratford, Jamie Honeychurch, Timothy M. Illidge
Journal: Blood
Blood (2013) 121 (2): 251–259.
https://doi.org/10.1182/blood-2012-05-432393
Published: 2013
Includes: Supplemental data
Journal Articles

Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species

Jamie Honeychurch, PhD, Waleed Alduaij, MRes, Eleanor Cheadle, PhD, Mahsa Azizyan, MSc, Helene Pelicano, PhD, Peng Huang, MD PhD, Andrei Ivanov, MD PhD, Mark S Cragg, PhD, Timothy M Illidge, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1651.
https://doi.org/10.1182/blood.V118.21.1651.1651
Published: 2011
Journal Articles

Fractionated 90 y Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy As An Initial Therapy of Follicular Lymphoma – First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria

Timothy M Illidge, MD, PhD, Ruth Pettengell, MD, Michael Bayne, MD, Steven Le Gouill, MD, PhD, Andrew Bates, MD, John Radford, MD, Jill Tipping, PhD, Maureen Zivanovic, PhD, Françoise kraeber-Bodere, MD, Emmanuel Malek, PhD, Huglo Damien, MD, Franck Morschhauser, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 102.
https://doi.org/10.1182/blood.V118.21.102.102
Published: 2011
Journal Articles

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

Clinical Trials & Observations
Youn H. Kim, Madeleine Duvic, Erik Obitz, Robert Gniadecki, Lars Iversen, Anders Österborg, Sean Whittaker, Timothy M. Illidge, Thomas Schwarz, Roland Kaufmann, Kevin Cooper, Kim M. Knudsen, Steen Lisby, Ole Baadsgaard, Susan J. Knox
Journal: Blood
Blood (2007) 109 (11): 4655–4662.
https://doi.org/10.1182/blood-2006-12-062877
Published: 2007
Journal Articles

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

Brief Report
Mark S. Cragg, Mike B. Bayne, Alison L. Tutt, Ruth R. French, Stephen Beers, Martin J. Glennie, Timothy M. Illidge
Journal: Blood
Blood (2004) 104 (8): 2540–2542.
https://doi.org/10.1182/blood-2004-05-1733
Published: 2004
Journal Articles

Apparent modulation of CD20 by rituximab: an alternative explanation

Mark S. Cragg, Mike C. Bayne, Timothy M. Illidge, Thomas Valerius, Peter W. N. Johnson, Martin J. Glennie
Journal: Blood
Blood (2004) 103 (10): 3989–3991.
https://doi.org/10.1182/blood-2003-12-4384
Published: 2004
Journal Articles

Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell–dependent immunity to B-cell lymphoma

Jamie Honeychurch, Martin J. Glennie, Peter W. M. Johnson, Timothy M. Illidge
Journal: Blood
Blood (2003) 102 (4): 1449–1457.
https://doi.org/10.1182/blood-2002-12-3717
Published: 2003
Journal Articles

The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma

Timothy M. Illidge, Mark S. Cragg, Harry M. McBride, Ruth R. French, Martin J. Glennie
Journal: Blood
Blood (1999) 94 (1): 233–243.
https://doi.org/10.1182/blood.V94.1.233.413a25_233_243
Published: 1999